In the study titled "Systematic analysis reveals key microRNAs as diagnostic and prognostic factors in progressive stages of lung cancer," authors Dietrich Kong, Ke Wang, Qiu-Ning Zhang, and Zhi-Tong Bing investigated the role of microRNAs in lung cancer progression. MicroRNAs are known to play a crucial role in various biological processes, including tumor development. However, their specific functions as biomarkers in cancer pathology remain unclear. The researchers focused on lung adenocarcinoma (LUAD) as a prototype case and integrated clinical information with transcript expression data to analyze the impact of microRNAs on diagnostic and prognostic factors at different stages of the disease. They employed dimension reduction techniques followed by unsupervised hierarchical clustering to identify unique expression patterns of microRNAs associated with diagnostic factors at various patient stages. To identify prognostic factors, the authors developed a classification framework called Light Gradient Boosting Machine (LightGBM) along with the SHAPley Additive explanation (SHAP) algorithm. This framework allowed them to screen for microRNAs that could serve as prognostic tools for monitoring lung cancer. Enrichment analyses revealed that both diagnostic and prognostic factors were enriched not only in cancer-related pathways but also involved essential cellular signaling transduction and immune responses. Furthermore, these key microRNAs were found to influence the survival risk of LUAD patients across all or specific stages. Some of these microRNAs even targeted important Transcription Factors (TF). The study identified five specific microRNAs - hsa-mir-196b, hsa-mir-31, hsa-mir-891a, hsa-mir-34c, and hsa-mir-653 - which showed potential as both diagnostic factors and prognostic tools for monitoring lung cancer. These findings provide valuable insights into the role of microRNAs in lung cancer progression and emphasize their potential clinical significance for diagnosis and prognosis of the disease. Overall, this systematic analysis expands our understanding of the diagnostic and prognostic factors associated with microRNAs in lung cancer. The identified microRNAs hold promise as potential biomarkers for monitoring disease progression and may contribute to improved patient outcomes in the future.
MicroRNAs are small molecules that are important in the development of tumors and can be used to identify lung cancer. The study looked at a specific type of lung cancer called lung adenocarcinoma and how microRNAs affect the diagnosis and prognosis at different stages of the disease. Scientists used special techniques to find patterns in how microRNAs are expressed and identified factors that help diagnose the cancer. They also developed a way to predict how the cancer will progress using a computer program. The study found that certain microRNAs can be used to diagnose and monitor lung cancer, providing important information for doctors."
Definitions
- MicroRNA: Small molecules that play a role in tumor development.
- Tumor: An abnormal growth of cells in the body.
- Biomarkers: Substances or characteristics that can indicate a disease or condition.
- Lung adenocarcinoma: A specific type of lung cancer.
- Diagnostic: Related to identifying or diagnosing a disease.
- Prognostic: Related to predicting how a disease will progress.
- Expression patterns: How genes or molecules are produced or shown in the body.
- Enrichment analyses: Examining if certain factors are more common in specific pathways or processes in the body.
- Pathways: Routes or processes within cells that control various functions.
- Cellular signaling transduction: Communication between cells through signals.
- Immune responses: How the body's immune system reacts to foreign substances or diseases.
Systematic Analysis Reveals Key MicroRNAs as Diagnostic and Prognostic Factors in Progressive Stages of Lung Cancer
Lung cancer is one of the leading causes of death worldwide, with an estimated 1.8 million new cases diagnosed each year. To improve patient outcomes, it is essential to identify reliable biomarkers for diagnosis and prognosis at different stages of the disease. In a recent study titled “Systematic analysis reveals key microRNAs as diagnostic and prognostic factors in progressive stages of lung cancer”, researchers Dietrich Kong, Ke Wang, Qiu-Ning Zhang, and Zhi-Tong Bing investigated the role of microRNAs (miRNAs) in lung adenocarcinoma (LUAD).
What are miRNAs?
MiRNAs are small noncoding RNAs that play a crucial role in various biological processes including tumor development. They regulate gene expression by targeting messenger RNA molecules which results in either inhibition or activation of protein production. Although their specific functions as biomarkers for cancer pathology remain unclear, they have been identified to be involved in several diseases including LUAD.
The Study
In this systematic analysis, the authors integrated clinical information with transcript expression data to analyze the impact of miRNA on diagnostic and prognostic factors at different stages of LUAD progression. Dimension reduction techniques followed by unsupervised hierarchical clustering were employed to identify unique expression patterns associated with diagnostic factors at various patient stages while a classification framework called Light Gradient Boosting Machine (LightGBM) along with SHAPley Additive explanation (SHAP) algorithm was used to screen for miRNA that could serve as prognostic tools for monitoring lung cancer progression.
Findings
Enrichment analyses revealed that both diagnostic and prognostic factors were enriched not only in cancer-related pathways but also involved essential cellular signaling transduction and immune responses. Furthermore, these key miRNA were found to influence survival risk across all or specific stages even targeting important Transcription Factors (TF). The study identified five specific miRNA - hsa-mir-196b, hsa-mir-31 , hsa-mir-891a , hsa-mir34c ,and hsa–mir–653 – which showed potential as both diagnostic factors and prognostic tools for monitoring lung cancer progression .
Conclusion
This systematic analysis expands our understanding into the role of miRNA on LUAD diagnosis and prognosis providing valuable insights into their potential clinical significance for improved patient outcomes in the future . The identified miRNA hold promise as potential biomarkers for monitoring disease progression more accurately than ever before .
MicroRNAs play an indispensable role in numerous biological processes ranging from organismic development to tumor progression.In oncology,these microRNAs constitute a fundamental regulation role in the pathology of cancer that provides the basis for probing into the influences on clinical features through transcriptome data. Previous work focused on machine learning (ML) for searching biomarkers in different cancer databases, but the functions of these biomarkers are fully not clear. Taking lung cancer as a prototype case of study. Through integrating clinical information into the transcripts expression data, we systematically analyzed the effect of microRNA on diagnostic and prognostic factors at deteriorative lung adenocarcinoma (LUAD). After dimension reduction, unsupervised hierarchical clustering was used to find the diagnostic factors which represent the unique expression patterns of microRNA at various patient's stages. In addition, we developed a classification framework, Light Gradient Boosting Machine (LightGBM) and SHAPley Additive explanation (SHAP) algorithm, to screen out the prognostic factors. Enrichment analyses show that the diagnostic and prognostic factors are not only enriched in cancer-related athways, but also involved in many vital cellular signaling transduction and immune responses. These key microRNAs also impact the survival risk of LUAD patients at all (or a specific) stage(s) and some of them target some important Transcription Factors (TF).The key finding is that five microRNAs (hsa-mir-196b, hsa-mir-31, hsa-mir-891a, hsa-mir-34c, and hsa-mir-653) can then serve as not only potential diagnostic factors but also prognostic tools in the monitoring of lung cancer.
